# US 2019/0314415 A1 · Rar selective agonists in combination with immune modulators for cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314415 A1
- Document ID: US20190314415A1
- Status: Published application
- Kind: A1
- Application number: 16/452,800
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2017-08-31
- Assignees: Io Therapeutics, Inc.
- Applicants: Io Therapeutics, Inc.
- Inventors: Roshantha A. Chandraratna; Martin E. Sanders
- Web page: https://patentgrep.com/patent/US20190314415A1

## CPC

- A61K 31/4965: Non-condensed pyrazines
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4255: {Mesothelin [MSLN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 31/69: Boron compounds
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of potentiating immune checkpoint inhibitor therapy comprising administering at least one differentiating retinoic acid receptor (RAR) active agent, wherein the differentiating RAR active agent is a RARα agonist, to a cancer patient who is receiving or is scheduled to receive, an immune checkpoint inhibitor antibody, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)
wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.

### Claim 32

A method of cancer immunotherapy comprising administering to a subject in need thereof an immune checkpoint inhibitor antibody and at least one differentiating RAR active agent, wherein the differentiating RAR active agent is a RARα agonist, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)
wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.

### Claim 33 (depends on 31)

The method of claim 31, further comprising administration of an immune checkpoint inhibitor antibody that is an inhibitor of at least one of CTLA-4, PD-1, TIM-3, LAG-3, PD-L1 ligand, B7-H3, B7-H4, BTLA, or is an ICOS or OX40 agonist.

### Claim 34 (depends on 1)

The method according to claim 1, wherein R4 is F, Cl, Br or I.

### Claim 35 (depends on 31)

The method of claim 31, wherein the RARα agonist is a compound having a structure of formula (II):
wherein R1 is H or C1-6 alkyl.

### Claim 36 (depends on 35)

The method of claim 35, wherein the RARα agonist is a compound having a structure of formula (III):

### Claim 37 (depends on 31)

The method of claim 31, wherein the cancer is a hematologic malignancy.

### Claim 38 (depends on 37)

The method according claim 37, wherein the hematologic malignancy is acute myeloid leukemia, chronic myelogenous leukemia (CML), accelerated CML, CML blast phase (CML-BP), acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes (MDS), refractory anemia (RA), RA with ringed sideroblasts, RA with excess blasts (RAEB), RAEB in transformation, or a myeloproliferative syndrome.

### Claim 39 (depends on 37)

The method according to claim 37, wherein the hematologic malignancy is acute myeloid leukemia.

### Claim 40 (depends on 37)

The method according to claim 37, wherein the hematologic malignancy is multiple myeloma.

### Claim 41 (depends on 31)

The method according to claim 31, wherein the cancer is a solid tumor.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the cancer is a solid tumor which can metastasize to the bone selected from pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, bronchoalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, progressive epithelial, primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, metastatic neuroendocrine tumor; brain tumor, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma.

### Claim 43 (depends on 32)

The method of claim 32, further comprising administration of an immune checkpoint inhibitor antibody that is an inhibitor of at least one of CTLA-4, PD-1, TIM-3, LAG-3, PD-L1 ligand, B7-H3, B7-H4, BTLA, or is an ICOS or OX40 agonist.

### Claim 44 (depends on 2)

The method according to claim 2, wherein R4 is F, Cl, Br or I.

### Claim 45 (depends on 32)

The method of claim 32, wherein the RARα agonist is a compound having a structure of formula (II):
wherein R1 is H or C1-6 alkyl.

### Claim 46 (depends on 45)

The method of claim 45, wherein the RARα agonist is a compound having a structure of formula (III):

### Claim 47 (depends on 32)

The method of claim 32, wherein the cancer is a hematologic malignancy.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the hematologic malignancy is acute myeloid leukemia.

### Claim 49 (depends on 47)

The method according to claim 47, wherein the hematologic malignancy is multiple myeloma.

### Claim 50 (depends on 32)

The method according to claim 32, wherein the cancer is a solid tumor.
